Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.

Tophaceous Gout

Crystalys Therapeutics250 participantsStarted Aug 2025

Birmingham, Alabama, United States • Foley, Alabama, United States • Gilbert, Arizona, United States +75 more locations

RECRUITINGPhase 2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

GoutGouty ArthritisHyperuricemia+4 more

Arthrosi Therapeutics25 participantsStarted Dec 2025

Margate, Florida, United States • Miami, Florida, United States • Tampa, Florida, United States +5 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients